LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (“COPD”) at CHEST Annual Meeting (“CHEST”) on Monday, October 21, 2019 at 02:30 AM CDT.

Kathleen Rickard, M.D., CMO at Verona Pharma, will expand on symptom data first announced by the Company on March 26, 2018 where ensifentrine produced clinically and statistically significant improvements in lung function as well as significant and progressive improvements in COPD symptoms. Results from the 4-week Phase 2b trial are available on Verona Pharma’s website here.

Details of Verona Pharma’s oral presentation are listed below and via the CHEST website here.

Oral Presentation/Poster: Poster E1037 – Unique dual phosphodiesterase 3/4 inhibitor, ensifentrine, significantly improves COPD symptoms including dyspnea
Presenter: Kathleen Rickard, M.D., CMO, Verona Pharma
Session: 4331 Electronic Posters 4
Date / Time: Monday, October 21, 2019 at 02:30 PM CDT / 08:30 PM BST / 03:30 PM ET
Location: Ernest N. Morial Convention Center, New Orleans; Exhibit Hall, Poster Area 4

About COPD
COPD is a progressive and life-threatening respiratory disease without a cure. The World Health Organization estimates that it will become the third leading cause of death worldwide by 2030. The condition damages the airways and the lungs, leading to debilitating breathlessness that has a devastating impact on performing basic daily activities such as getting out of bed, showering, eating and walking. In the United States alone, the total annual medical costs related to COPD are projected to rise to $49 billion in 2020. About 1.2 million US COPD patients on dual/triple inhaled therapy (LAMA/LABA +/- ICS) remain uncontrolled, experiencing symptoms that impair quality of life. These patients urgently need better treatments.

About Ensifentrine
Nebulized ensifentrine (RPL554) has shown significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in Verona Pharma’s prior Phase 2 clinical studies in patients with moderate-to-severe COPD. In addition, nebulized ensifentrine showed further improved lung function and reduced lung volumes in patients taking standard short- and long-acting bronchodilator therapy, including maximum bronchodilator treatment with dual/triple therapy. Ensifentrine has been well tolerated in clinical trials involving more than 800 people to date.